Cytokines and outcome in the SWOG cohort and MER/SWOG meta-analysis
| . | SWOG cohort (N = 183) . | Meta-analysis on chemotherapy treated patients (total N = 264) . | |||
|---|---|---|---|---|---|
| . | % Elevated . | EFS HR* (95% CI) . | P . | EFS HR (95% CI) . | P . |
| HGF | 18 | 0.80 (0.44-1.45) | .46 | 1.21 (0.73-1.98) | .46 |
| IL-8 | 27 | 1.27 (0.79-2.04) | .32 | 1.45 (0.94-2.25) | .096 |
| IL-12 | 52 | 1.17 (0.74-1.83) | .50 | 1.05 (0.71-1.56) | .79 |
| IL-2R | 84 | 2.41 (1.04-5.58) | .04 | 2.05 (1.16-3.61) | .013 |
| IL-1RA | 21 | 1.14 (0.67-1.94) | .62 | 1.57 (1.02-2.42) | .042 |
| CXCL9 | 49 | 1.50 (0.93-2.43) | .10 | 1.96 (1.30-2.95) | .0012 |
| . | SWOG cohort (N = 183) . | Meta-analysis on chemotherapy treated patients (total N = 264) . | |||
|---|---|---|---|---|---|
| . | % Elevated . | EFS HR* (95% CI) . | P . | EFS HR (95% CI) . | P . |
| HGF | 18 | 0.80 (0.44-1.45) | .46 | 1.21 (0.73-1.98) | .46 |
| IL-8 | 27 | 1.27 (0.79-2.04) | .32 | 1.45 (0.94-2.25) | .096 |
| IL-12 | 52 | 1.17 (0.74-1.83) | .50 | 1.05 (0.71-1.56) | .79 |
| IL-2R | 84 | 2.41 (1.04-5.58) | .04 | 2.05 (1.16-3.61) | .013 |
| IL-1RA | 21 | 1.14 (0.67-1.94) | .62 | 1.57 (1.02-2.42) | .042 |
| CXCL9 | 49 | 1.50 (0.93-2.43) | .10 | 1.96 (1.30-2.95) | .0012 |
Adjusted for IPI and initial therapy (S9800 vs S9911 vs S0016).